AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16616230 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1404
Study 16616230 — intervention group
Group type: EXPERIMENTAL
Intervention: overall cohort
Number of subjects: 1404
Study 12798527 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (tablets containing 114 mg of isoflavonoids)
Number of subjects: 62
Study 12798527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12798527 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 62
Study 11307095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (400 mg) given orally, single dose
Number of subjects: 100
Study 11307095 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (1000/200 mg) given by intravenous infusion, three doses
Number of subjects: 100
Study 11307095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 100
Study 11307095 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 100
Study 7644448 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of practice
Number of subjects: 81
Study 7644448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to detect lumps in a model
Number of subjects: 81
Study 2528295 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (20 micrograms)
Number of subjects: 0
Study 2528295 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (40 micrograms)
Number of subjects: 0
Study 2528295 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (zero, one, two, six months schedule)
Number of subjects: 0
Study 2528295 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant DNA hepatitis B vaccine (zero, one, two, twelve months schedule)
Number of subjects: 0
Study 391629 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound analgesic with chlormezanone
Number of subjects: 0
Study 391629 — intervention group
Group type: COMPARATOR
Intervention: Compound analgesic (placebo-controlled)
Number of subjects: 0
Study 31960066 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomo + repetitive, task-specific practice
Number of subjects: 34
Study 31960066 — intervention group
Group type: COMPARATOR
Intervention: Repetitive, task-specific practice only
Number of subjects: 34
Study 31960066 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomo only
Number of subjects: 34
Study 30839428 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated opioid-tapering advice
Number of subjects: 196
Study 30839428 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated opioid-change advice
Number of subjects: 196
Study 30839428 — intervention group
Group type: COMPARATOR
Intervention: Simulated opioid-maintenance advice
Number of subjects: 196
Study 28781336 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS), twice a day, for three months
Number of subjects: 126
Study 28781336 — intervention group
Group type: COMPARATOR
Intervention: Short-acting β2-adrenoreceptor agonist (SABA), inhalation only if necessary
Number of subjects: 126
Study 28781336 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 126
Study 25935057 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid and HBO (group 1)
Number of subjects: 58
Study 25935057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid (ITS) with systemic steroid and HBO (group 2)
Number of subjects: 58
Study 23351408 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 11
Study 23351408 — intervention group
Group type: COMPARATOR
Intervention: Cod protein
Number of subjects: 11
Study 23351408 — intervention group
Group type: COMPARATOR
Intervention: Gluten
Number of subjects: 11
Study 23351408 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 11
Study 21701791 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (4 weeks)
Number of subjects: 0
Study 21701791 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (2 weeks)
Number of subjects: 0
Study 21701791 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (4 weeks)
Number of subjects: 0
Study 19155581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron, thiamine, riboflavin, folic acid, niacinamide, zinc and calcium (Group III)
Number of subjects: 226
Study 19155581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron (Group II)
Number of subjects: 226
Study 19155581 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (Group I)
Number of subjects: 226
Study 16449425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) + Medication Adherence Training (MAT)
Number of subjects: 130
Study 16449425 — intervention group
Group type: COMPARATOR
Intervention: MAT-Only
Number of subjects: 130
Study 12818051 — intervention group
Group type: COMPARATOR
Intervention: Overlay technique
Number of subjects: 60
Study 12818051 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlay technique
Number of subjects: 60
Study 11009046 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 18
Study 11009046 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 18
Study 11009046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9183592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation patients
Number of subjects: 27
Study 8333006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 15
Study 8333006 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 15
Study 3581104 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine, hydroxyurea, and dacarbazine chemotherapy
Number of subjects: 0
Study 3581104 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no chemotherapy)
Number of subjects: 0
Study 3581104 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment and control arms
Number of subjects: 0
Study 30316931 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention consisting of staff education and pamphlet and video decision aids (DAs)
Number of subjects: 182
Study 30316931 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 182
Study 30316931 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 182
Study 30316931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (SDM intervention)
Number of subjects: 182
Study 26173655 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6.0 mg/kg body mass)
Number of subjects: 13
Study 26173655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24118269 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) up to 180 mg/day
Number of subjects: 54
Study 24118269 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 54
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 4700
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4700
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 4700
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: Neurocognitive dysfunction
Number of subjects: 4700
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: Recurrence of angina
Number of subjects: 4700
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular mortality
Number of subjects: 4700
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusions
Number of subjects: 4700
Study 22172429 — intervention group
Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 4700
Study 20954288 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2147
Study 20954288 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 2147
Study 18477661 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH and T (GHT)
Number of subjects: 21
Study 18477661 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (GH)
Number of subjects: 21
Study 18477661 — intervention group
Group type: EXPERIMENTAL
Intervention: T (testosterone)
Number of subjects: 21
Study 18477661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15990759 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Disease Management (DM) programs
Number of subjects: 5752
Study 15990759 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care or no DM)
Number of subjects: 5752
Study 12800128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital- and clinic-based smoking cessation interventions
Number of subjects: 0
Study 12800128 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling and pharmacotherapy
Number of subjects: 0
Study 12800128 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine implementation of smoking cessation methods
Number of subjects: 0
Study 10569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 90
Study 10569324 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 90
Study 10569324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10569324 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (controls)
Number of subjects: 90
Study 9162350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sextant biopsy
Number of subjects: 31
Study 9162350 — intervention group
Group type: COMPARATOR
Intervention: Directed ultrasound guided biopsy
Number of subjects: 31
Study 1853462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (GaAlAs, 830 nm, continuous)
Number of subjects: 36
Study 1853462 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 6401928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 4% ophthalmic solution
Number of subjects: 31
Study 6401928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30137410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg (experiment DG)
Number of subjects: 15
Study 30137410 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus saline infusion (experiment DS)
Number of subjects: 15
Study 30137410 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (experiment D)
Number of subjects: 15
Study 29609923 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Jiedu Huayu Decoction (FJHD)
Number of subjects: 284
Study 29609923 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with placebo
Number of subjects: 284
Study 27081185 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (CB), n = 759
Number of subjects: 1800
Study 27081185 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel hydrogen sulfate (CHS), n = 798
Number of subjects: 1800
Study 25011952 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 44
Study 25011952 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 44
Study 22047637 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy sessions with significant others present
Number of subjects: 0
Study 22047637 — intervention group
Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy sessions without significant others (implied control)
Number of subjects: 0
Study 19940323 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-exercise program
Number of subjects: 32
Study 19940323 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility-exercise program
Number of subjects: 32
Study 17508971 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 100 microg/day
Number of subjects: 0
Study 17508971 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP 200 microg/day
Number of subjects: 0
Study 17508971 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-BDP 800 microg/day
Number of subjects: 0
Study 17508971 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 microg/day
Number of subjects: 0
Study 17508971 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast with HFA-BDP 400 microg
Number of subjects: 0
Study 17508971 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast with CFC-BDP 800 microg
Number of subjects: 0
Study 15030959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation for 8 weeks post discharge
Number of subjects: 0
Study 15030959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study 11311658 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes (paclitaxel and docetaxel)
Number of subjects: 0
Study 11311658 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes (paclitaxel and docetaxel) with concurrent radiotherapy
Number of subjects: 0
Study 9797945 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually perceived vertical (VPV)
Number of subjects: 8
Study 9797945 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually perceived horizontal (VPH)
Number of subjects: 8
Study 9797945 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair rotation speed of 2 degrees/s and 1/2 degree/s
Number of subjects: 8
Study 8046313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with a target INR of 2.0-2.85
Number of subjects: 1124
Study 2973188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 micrograms
Number of subjects: 110
Study 2973188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 micrograms
Number of subjects: 110
Study 2973188 — intervention group
Group type: COMPARATOR
Intervention: 10 micrograms
Number of subjects: 110
Study 2973188 — intervention group
Group type: COMPARATOR
Intervention: 5 micrograms
Number of subjects: 110
Study 2973188 — intervention group
Group type: COMPARATOR
Intervention: 2.5 micrograms
Number of subjects: 110
Study 2973188 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 110
Study 30452479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination induced condition
Number of subjects: 61
Study 30452479 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study 28207330 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 746
Study 28207330 — intervention group
Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 746
Study 26715479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 µg (R2.5)
Number of subjects: 2784
Study 26715479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 µg (R5)
Number of subjects: 2784
Study 26715479 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 µg (HH18)
Number of subjects: 2784
Study 23760946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (cognitive training plus reality orientation therapy)
Number of subjects: 9
Study 23760946 — intervention group
Group type: COMPARATOR
Intervention: Aspecific stimulation
Number of subjects: 9
Study 22030225 — intervention group
Group type: COMPARATOR
Intervention: High-oleic sunflower oil (control)
Number of subjects: 50
Study 22030225 — intervention group
Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 50
Study 22030225 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified palm olein (IPO)
Number of subjects: 50
Study 22030225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 50
Study 19638785 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent rater (IR) direct observation system for CVC insertion training
Number of subjects: 38
Study 19638785 — intervention group
Group type: EXPERIMENTAL
Intervention: Training module for IRs
Number of subjects: 38
Study 16778461 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate paste applied twice daily for 5 days at dosages of 1 and 2 mg/cm(2)
Number of subjects: 15
Study 16778461 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum and 15% zinc oxide pastes (without miconazole) applied twice daily for 5 days
Number of subjects: 15
Study 16778461 — intervention group
Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 15
Study 15527668 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise supplemented with an 8-week class-based exercise programme
Number of subjects: 214
Study 15527668 — intervention group
Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 214
Study 11259886 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed standard tracheal tube
Number of subjects: 50
Study 11259886 — intervention group
Group type: COMPARATOR
Intervention: Wire reinforced tracheal tube
Number of subjects: 50
Study 9296232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 1 mg/mL
Number of subjects: 24
Study 9296232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 2 mg/mL
Number of subjects: 24
Study 9296232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 4 mg/mL
Number of subjects: 24
Study 9296232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 5 mg/mL
Number of subjects: 24
Study 9296232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8393581 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP; 600 micrograms/day) plus salbutamol (S; 900 micrograms/day)
Number of subjects: 12
Study 8393581 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (S; 900 micrograms/day) alone
Number of subjects: 12
Study 2947615 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal flap method (Rehrmann, 1936)
Number of subjects: 86
Study 2947615 — intervention group
Group type: COMPARATOR
Intervention: Palatal flap method (Ashley, 1939)
Number of subjects: 86
Study 29466057 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate (ALN) 70 mg weekly
Number of subjects: 161
Study 29466057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg once yearly
Number of subjects: 161
Study 27550619 — intervention group
Group type: EXPERIMENTAL
Intervention: HSC‐CM intervention
Number of subjects: 60
Study 27550619 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 25842457 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gel (TG) - 5% sodium fluoride, 5% potassium oxalate, 10% strontium chloride
Number of subjects: 107
Study 25842457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel (FG) - 2% sodium fluoride
Number of subjects: 107
Study 25842457 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (PG)
Number of subjects: 107
Study 23034729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening invitation (invited group)
Number of subjects: 67770
Study 23034729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 67770
Study 23034729 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 67770
Study 23034729 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening invitation
Number of subjects: 67770
Study 20653224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D auditory cues present in dynamic environments
Number of subjects: 8
Study 20653224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D auditory cues present in static environments
Number of subjects: 8
Study 20653224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D auditory cues present
Number of subjects: 8
Study 20653224 — intervention group
Group type: COMPARATOR
Intervention: 3-D auditory cues absent
Number of subjects: 8
Study 17595194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus weight management
Number of subjects: 10742
Study 17595194 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard care for weight management
Number of subjects: 10742
Study 16293546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received asthma kits (including peak flow meter, MDI spacer device, educational materials), training of health center staff in asthma care guidelines, and tools/templates for practice-level systems change.
Number of subjects: 16
Study 16293546 — intervention group
Group type: COMPARATOR
Intervention: Control group received only copies of the national asthma guidelines.
Number of subjects: 16
Study 11980851 — intervention group
Group type: EXPERIMENTAL
Intervention: OBF pneumotonometer
Number of subjects: 181
Study 11980851 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Number of subjects: 181
Study 11980851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 181
Study 11980851 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 181
Study 10222609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education for five months (group lectures and individual counseling)
Number of subjects: 53
Study 10222609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during the first five months)
Number of subjects: 53
Study 10222609 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants (n = 53)
Number of subjects: 53
Study 10222609 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who successfully stopped smoking
Number of subjects: 53
Study 7835571 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1N HCl
Number of subjects: 25
Study 7835571 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 25
Study 7835571 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 25
Study 7835571 — intervention group
Group type: COMPARATOR
Intervention: Balloon stretch
Number of subjects: 25